Search results for " Europe" in Articles / App Notes
Article
Biopharma Manufacturers Respond to Ebola Crisis
Demand for new therapies and vaccines spotlights production challenges.
Oct 1, 2014
By: Jill Wechsler
BioPharm International
Volume 27, Issue 10, pp. 8-9
The development of new tr…
Article
A Q&A With Dr. Anurag Rathore About the Future of QbD, Part I
Even biosimilar manufacturers based outside North America and Europe are also implementing QbD. But every company is in the process of trying to figure out better (as in more efficient with respect to…
Article
Pharma Investments Reflect Key Industry Trends
In Europe, Merck Serono is spending $68 to $69 million (€50 million) to modernize its fill-finish plant in Bari, Italy. Merck’s Allergopharma unit, meanwhile, is constructing a $55 million (€40 millio…
Article
Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic Products
Reason is UK business manager, Life Science Services, Group Manager SGS M-Scan Europe.
Article
Q&A with Eric Langer, about the evolution of the role of CMO’s in Bioprocessing
In Europe, 53% of decision makers see a shrinking talent pool as an on-going problem.
CMO’s are seen increasingly as valuable partners because they work on a wide variety of projects, so their t…
Article
Global Expansion Shapes Drug Oversight
At the same time, FDA and the European Medicines Agency (EMA) annouced plans to expand their many collaborative programs, including renewal of a pilot program that allows for parallel review and consu…
Article
Q&As with Industry Leaders
…cess Development for Advanced Therapeutics
Felicity Thomas, Pharmaceutical Technology Europe
Peter Guterstam, Product Manager, Advanced Therapeutics Downstream Solutions, Cytiva
…
Article
2014 Manufacturing Trends and Outlook
…dation, and laboratory management titles at branded and generic-drug companies in the United States, Europe, and Asia. More than half of the respondents work for organizations that produce both small…
Article
Drugs, At What Cost?
Competition generated through established biosimilar pathways will drive down the high costs of biologics in Europe, the US, and some emerging countries. However, in markets with less rigorous IP prot…
Article
Navigating Emerging Markets: Middle East and North Africa
Turkey, for example, has introduced market exclusivity as part of its efforts to become a European Union (EU) member state and has introduced other reforms to bring greater consistency with the rest o…